Array
(
[1576408352] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1576409973] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1576410481] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1576411952] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576416726] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1576417474] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576423073] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1576426024] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576429011] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576480112] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576486171] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576491311] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576491352] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1576504199] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[ccee4635eaa1c5c68847742cf6f56334] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1576504199
)
)
)
)
[1576508400] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1576763399] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[9b181c9e6b126f6f93b7b0404ada1528] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1576763399
)
)
)
)
[1580169600] => Array
(
[publish_future_post] => Array
(
[2d492587fa52e9c78f7043ddf937b0a1] => Array
(
[schedule] =>
[args] => Array
(
[0] => 18611
)
)
[dea3edad73162f380bc9dc44fa3407bf] => Array
(
[schedule] =>
[args] => Array
(
[0] => 19670
)
)
[2caa9c58a241c4f77a6856802c1b43fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 20734
)
)
[307b37ba29b8cd716eafa809661756e3] => Array
(
[schedule] =>
[args] => Array
(
[0] => 22852
)
)
[365be9eba8e62abb0c0d4bfe013a2687] => Array
(
[schedule] =>
[args] => Array
(
[0] => 23918
)
)
[0e942b20ffb9550322105263ad82126f] => Array
(
[schedule] =>
[args] => Array
(
[0] => 24977
)
)
[661c5eb39689fe2133ff7986ac6628fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 26036
)
)
[75562b264e355915e4dea97042a28f7e] => Array
(
[schedule] =>
[args] => Array
(
[0] => 27095
)
)
[11cf4e8a6f842b0115881551a29c47f6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 28154
)
)
[55a38aaca11da398c854cb29a7d4f5e6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 30272
)
)
[f8cbc904676c235c7057ec965c01c023] => Array
(
[schedule] =>
[args] => Array
(
[0] => 32390
)
)
)
)
[1583794819] => Array
(
[publish_future_post] => Array
(
[9d993985746691420cd7524448c48a23] => Array
(
[schedule] =>
[args] => Array
(
[0] => 448880
)
)
)
)
[1601157627] => Array
(
[publish_future_post] => Array
(
[aa3f9c41dd8e97586795881a0c603b8d] => Array
(
[schedule] =>
[args] => Array
(
[0] => 472787
)
)
)
)
)
Etiquetas: Actualización de la Información, Actualización sobre restricciones de uso, AEMPS, Agencia española de medicamentos y productos sanitarios, Agonistas dopaminérgicos ergóticos, Azacitidina, BINOCRIT, Cambios de especial interés sanitario en medicamentos ya autorizados, Cetuximab, Comité de Seguridad de Medicamentos de Uso Humano, CSMH, Darunavir, Epoetina alfa, Erbitux, Eszopiclona, Información dirigida a profesionales sanitarios, Información sobre seguridad, informe, Losartán potásico, LUNIVIA, Madrid, medicamentos, Mensual, Nuevas formulaciones de medicamentos ya autorizados, Nuevos medicamentos, octubre 2008, Orlistat, PEGASYS, Peginterferón alfa 2A, PREZISTA, Productos sanitarios, Resumen de la nota informativa, Rimonabant, salud, Sanidad, Terapia Hormonal en la Menopausia, Terapia hormonal sustitutiva, Uso humano, VIDAZA.
Utilizamos cookies propias y de terceros para recopilar información que ayuda a optimizar su visita. Las cookies no se utilizan para recoger información de carácter personal. Usted puede permitir su uso o rechazarlo, también puede cambiar su configuración siempre que lo desee. Al continuar con la navegación entendemos que se acepta nuestra política de cookies.
x.gif)